Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 7/20 | 0.46 |
| ▸ | TSG101 | Q99816 | 10/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | OXTR | P30559 | 1/20 | 0.42 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.42 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10182947 | 0.95 | PRMT5 (0.51) | TACR2PRMT5WDR77TSG101MEN1 | |
| SCHEMBL15591315 | 0.95 | PRMT5 (0.51) | TACR2PRMT5WDR77TSG101MEN1 | |
| SCHEMBL10167164 | 0.92 | TACR2 (0.53) | TACR2PRMT5WDR77TSG101MEN1 | |
| SCHEMBL15099968 | 0.92 | PRMT5 (0.50) | TACR2PRMT5WDR77TSG101MEN1 | |
| SCHEMBL13492856 | 0.91 | PRMT5 (0.48) | TACR2PRMT5WDR77TSG101MEN1 | |
| SCHEMBL12837921 | 0.89 | MDM2 (0.42) | TACR2PRMT5WDR77TSG101MEN1 | |
| SCHEMBL15088335 | 0.89 | PRMT5 (0.48) | TACR2PRMT5WDR77TSG101MEN1 | |
| SCHEMBL18595987 | 0.86 | PRMT5 (0.49) | TACR2PRMT5WDR77TSG101 | |
| SCHEMBL14144739 | 0.76 | ALB (0.51) | TACR2OXTRAVPR1AAVPR1B | |
| SCHEMBL15489018 | 0.69 | ALB (0.49) | TACR2TSG101MEN1OXTRAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | TACR2 3952/4885PRMT5 148/4885WDR77 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.